Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled time : 12:15 save search
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
Published: 2021-11-10 (Crawled : 12:15) - globenewswire.com
GRTS | $0.7521 1.13% 310K
|
Health Technology
|
| O: -1.34%
H: 9.31%
C: 1.9%
covid positive vaccine preclinical sars-cov-2 pre-clinical
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-11-09 (Crawled : 12:15) - globenewswire.com
CMPS | $8.67 2.97% 88K
|
Health Technology
|
| O: -17.57%
H: 3.31%
C: -11.45%
treatment positive therapy results topline depression trial comp360 psilocybin
Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III
Published: 2021-10-29 (Crawled : 12:15) - globenewswire.com
IMMP | News | $2.23 1.36% 18K
|
Health Technology
|
| O: 3.33%
H: 1.61%
C: -1.61%
ema positive
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
IFRX | $1.32 4.76% 65K
|
Health Technology
|
| O: 1.75%
H: 3.09%
C: -1.72%
positive
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
Published: 2021-10-08 (Crawled : 12:15) - globenewswire.com
FBIO | $1.765 -2.49% 90K
|
Health Technology
|
| O: -0.34%
H: 3.41%
C: 2.05%
positive biotech iot conference
Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
Published: 2021-10-06 (Crawled : 12:15) - prnewswire.com
VIRX | $0.909 9.2K
|
Manufacturing
|
| O: -1.69%
H: 3.18%
C: 0.27%
solid tumors phase 1 positive trial phase 1b phase 2b
Otonomo Acquires Neura - Expanding its Pole Position from the Automotive to Mobility and Transportation Industries
Published: 2021-10-05 (Crawled : 12:15) - globenewswire.com
OTMO | $5.3 4.15% 1M
|
|
| O: 5.22%
H: 9.35%
C: 9.35%
automotive positive
Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
Published: 2021-10-01 (Crawled : 12:15) - prnewswire.com
PGEN | $1.325 0.38% 96K
|
Health Technology
|
| O: 0.0%
H: 3.26%
C: 2.4%
diabetes phase 1 positive therapy iot phase 1b designation phase 2b
Palo Alto Networks Positioned as a Leader in 2021 Gartner Magic Quadrant for WAN Edge Infrastructure
Published: 2021-10-01 (Crawled : 12:15) - prnewswire.com
PANW | News | $282.87 0.62% 1.5M
|
Electronic Technology
|
| O: 0.32%
H: 1.38%
C: 1.24%
IT | News | $446.49 -0.69% 87K
|
Commercial Services
|
| O: 0.53%
H: 1.31%
C: 0.24%
positive
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
Published: 2021-09-28 (Crawled : 12:15) - globenewswire.com
OTLK P | $8.375 1.03% 63K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: -3.08%
positive phase 3 trial
Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study
Published: 2021-09-22 (Crawled : 12:15) - globenewswire.com
THTX | $1.29 840
|
Health Technology
|
| O: -1.12%
H: 6.23%
C: 6.23%
positive results positive results
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Published: 2021-09-20 (Crawled : 12:15) - biospace.com/
EDSA | $4.47 2.52% 1.4K
|
Health Technology
|
| O: 68.6%
H: 26.98%
C: 26.14%
covid phase 2 positive antibody biotech iot covid-19
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
Published: 2021-09-15 (Crawled : 12:15) - globenewswire.com
ATAI | $1.965 2.88% 360K
|
Manufacturing
|
| O: -0.7%
H: 2.71%
C: -2.0%
positive life science
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
Published: 2021-09-13 (Crawled : 12:15) - globenewswire.com
OTLK P | $8.375 1.03% 63K
|
Health Technology
|
| O: 1.61%
H: 2.57%
C: -0.4%
positive retina conference
FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed PatientsExpanded Depression Indication Further Demonstrates Company’s Leadership Position
Published: 2021-08-18 (Crawled : 12:15) - biospace.com/
BWAY | $4.99 4.18% 20K
|
Health Technology
|
| O: 13.99%
H: 20.05%
C: -3.04%
fda depression positive fda clearance
Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387
Published: 2021-07-29 (Crawled : 12:15) - globenewswire.com
TFFP | $3.135 640
|
Health Technology
|
| O: 2.89%
H: 0.0%
C: -1.57%
covid anti-covid positive antibody sars-cov-2 in vitro
UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
Published: 2021-07-23 (Crawled : 12:15) - globenewswire.com
UBX | $1.51 21K
|
Health Technology
|
| O: 1.56%
H: 1.79%
C: -1.02%
disease eye phase 1 positive eye disease retina biotech technology iot trial ubx1325
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
Published: 2021-07-13 (Crawled : 12:15) - ir.hoththerapeutics.com
HOTH | $1.18 740
|
Health Technology
|
| O: 0.67%
H: 0.67%
C: -3.33%
treatment acne potential positive results
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer
Published: 2021-07-09 (Crawled : 12:15) - globenewswire.com
GALT | $3.27 -3.25% 23K
|
Health Technology
|
| O: 43.48%
H: 11.11%
C: -12.88%
phase 1 positive results cancer trial topline galectin-3 phase 1b keytruda phase 2b
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
Published: 2021-07-09 (Crawled : 12:15) - globenewswire.com
MTEM | $1.485 2K
|
Health Technology
|
| O: 0.51%
H: 0.99%
C: 0.64%
solid tumors phase 1 positive molecular phase 2
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.